title: Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth.
abstract: We have analysed the results of semi-solid bone marrow cultures in 296 patients with de novo acute myeloblastic leukaemia (AML) and correlated them with the leukaemic karyotype. A favourable prognostic karyotype was found in 52 patients (group A, 18.3%), an intermediate karyotype in 163 patients (group B, 57.4%), and unfavourable cytogenetics were observed in 69 patients (group C, 24.3%). Median colony growth according to the three risk groups was 2 (range 0--344) in group A, 14.5 (range 0--5000) in group B and 50.0 (0--3000) in group C (A vs. B, P < 0.001; A vs. C, P < 0.001; B vs. C, P < 0.01). Among the patients treated with chemotherapy (n = 257), median colony growth was 10 (range 0-5000) in those who achieved complete remission (CR) compared with 56.5 (range 0-1000) in patients without remission (NR) (P = 0.002). The median colony growth of all patients [13/10(5) bone marrow mononuclear cells (BMMCs); range 0--5000] significantly discriminated between patients regarding survival (OS 11 vs. 7 months, P = 0.044). However, multiple Cox regression analysis revealed cytogenetic risk groups as the most important predictor for achieving CR, disease-free and overall survival, with colony growth adding no additional prognostic information. In 64 patients, colony growth was also investigated without the addition of exogenous cytokines. Interestingly, none of the patients with a favourable karyotype exhibited autonomous growth, whereas 50% with an intermediate and 73% of patients with an unfavourable karyotype displayed either partial or full autonomous growth in vitro (P = 0.0004). Our data suggest that the growth potential of the leukaemic clone seems to be critically influenced by the molecular changes emerging from chromosomal abnormalities.
authors.affiliation: Department of Internal Medicine I, University of Vienna, Vienna, Austria. Leopold.ohler@akh-wien.ac.at
authors.forename: L
authors.initials: L
authors.lastname: Ohler
authors.forename: A
authors.initials: A
authors.lastname: Berer
authors.forename: D
authors.initials: D
authors.lastname: Aletaha
authors.forename: E
authors.initials: E
authors.lastname: Kabrna
authors.forename: G
authors.initials: G
authors.lastname: Heinze
authors.forename: B
authors.initials: B
authors.lastname: Streubel
authors.forename: C
authors.initials: C
authors.lastname: Fonatsch
authors.forename: O A
authors.initials: OA
authors.lastname: Haas
authors.forename: K
authors.initials: K
authors.lastname: Lechner
authors.forename: K
authors.initials: K
authors.lastname: Geissler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001854:Bone Marrow Cells / Q000473:pathology*; D002455:Cell Division; D002869:Chromosome Aberrations; D025063:Chromosome Disorders; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000473:pathology*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction; D012307:Risk Factors